Gilead Sciences (GILD) Tops Q4 EPS by 22c; Approves Dividend Program, $15B Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Gilead Sciences (GILD) Tops Q4 EPS by 22c; Approves Dividend Program, $15B Buyback
February 4, 2015 9:08 AM EST
Cowen analyst Phil Nadeau maintained an Outperform rating and $125 price target on Gilead Sciences (NASDAQ: GILD) following solid Q4 results, in-line 2015 sales guidance but commentary that did little to quell fears.
Nadeau commented, "GILD reported Q4:14 HCV sales ahead of consensus, and provided... More
February 4, 2015 9:04 AM EST
RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $118.00 (from $125.00). The change follows Q4 results. Overall analyst Michael J. Yee thinks the stock is cheap, with lots of optionality.
" ...GILD spooked investors with 2015 HCV guidance of "gross-to-net" rebates of 46%, which was higher than consensus 30%+, implying net pricing lower and competitive deals to... More
February 4, 2015 8:54 AM EST
Piper Jaffray analyst Joshua Schimmer weighed in on Gilead Sciences (NASDAQ: GILD) following solid Q4 results but noted guidance was a letdown. The firm maintained an Overweight rating and trimmed its price target to $116.00 (from $120.00).
Schimmer commented, "GILD reported a solid 4Q... More
February 4, 2015 8:26 AM EST
Goldman Sachs maintained a Neutral rating on Gilead Sciences (NASDAQ: GILD) and lowered its price target to $85.00 (from $96.00). The change follows Q4 results. Analyst Terence Flynn noted HepC pricing dynamics surprised to the downside.
"GILD guided to a 46% gross-to-net on US hepC pricing in 2015 (vs.... More
February 4, 2015 8:16 AM EST
Needham & Company analyst Alan Carr lowered estimates on Gilead Sciences (NASDAQ: GILD) following Q4 results but maintained a Buy rating and price target of $120.
Carr commented, "4Q14 Sovaldi sales were $1.73B, compared to our $1.90B estimate. Ex-U.S. sales were lower than... More
February 4, 2015 7:40 AM EST
Nomura Securities analyst M. Ian Somaiya trimmed his price target on Buy-rated Gilead Sciences (NASDAQ: GILD) to $141.00 (from $146.00) following results after the close.
Somaiya commented, "We expect the shock of aggressive discounting by Gilead (46% vs. our 20% estimate) on its HCV drugs to lead to... More
February 4, 2015 7:11 AM EST
Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) saying they are incrementally negative following 4Q14 earnings call.
Skorney commented, "A sizeable beat, new dividend and massive share buyback program aren't enough to offset the disappointment in... More
February 3, 2015 4:07 PM EST
Gilead Sciences (NASDAQ: GILD) announced that the companys Board of Directors has authorized a dividend program under which the company intends to pay quarterly dividends of $0.43 per share, beginning in the second quarter of 2015, subject to quarterly declarations by the Board of Directors.
The Board of Directors also approved the... More
